Holen Sie sich die Stockscreener-App
17.17
0.62%
0.14
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛
MoonLake price target raised to $70 from $45 at Clear Street - TipRanks
Clear Street raises Moonlake stock price target on IL-17 data By Investing.com - Investing.com Australia
Clear Street raises Moonlake stock price target on IL-17 data - Investing.com
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Widening Annual Net Loss Amid Share Price Gains - simplywall.st
Trading the Move, Not the Narrative: (MLTX) Edition - Stock Traders Daily
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - MSN
Is MoonLake Immunotherapeutics stock a smart buy before Fed meeting2026 EndofMonth & Verified Short-Term Trading Plans - Naître et grandir
TD Asset Management Inc Lowers Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat
MoonLake stock soars as biotech fund reloads, takeover chatter ignites - MSN
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Positive Phase 2 Sonelokimab Results - simplywall.st
MoonLake Therapeutics Stock Sparks Retail Frenzy Ahead Of New York Summit — Traders See 'Nonstop Catalysts' Through 2026 - Stocktwits
HC Wainwright Issues Negative Outlook for MLTX Earnings - MarketBeat
What is HC Wainwright's Estimate for MLTX FY2027 Earnings? - MarketBeat
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Exploring a 34.94% Upside in the Biotech Sphere - DirectorsTalk Interviews
Cantor Fitzgerald reiterates Moonlake stock rating on axSpA potential - Investing.com
MoonLake Immunotherapeutics (MLTX) Is Down 6.3% After Wider 2025 Loss And SLK BLA Timeline Update – Has The Bull Case Changed? - Sahm
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright - TipRanks
Moonlake Immunotherapeutics stock price target raised to $40 by H.C. Wainwright on trial results - Investing.com India
MLTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Royal Bank Of Canada Boosts MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $13.00 - MarketBeat
Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update - Finviz
Goldman Questions MoonLake Immunotherapeutics’ (MLTX) Sonelokimab Approval Odds Despite Pipeline Update - Yahoo Finance
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
RBC Raises Price Target on MoonLake Immunotherapeutics to $13 From $12, Keeps Sector Perform, Speculative Risk - marketscreener.com
MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer - TipRanks
Stifel Downgrades MoonLake Immunotherapeutics(MLTX.US) to Hold Rating, Cuts Target Price to $19 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Mixed Share Price Performance And Premium P/B Ratio - Yahoo Finance
MoonLake’s Sonelokimab Data Sharpens Risk Reward Profile Before Phase 3 - simplywall.st
MoonLake Immunotherapeutics (MLTX) Is Down 6.7% After Mixed 2025 Results And AxSpA Data UpdateWhat's Changed - Yahoo Finance
MoonLake shares climb on encouraging AXSPA trial results - MSN
Goldman Sachs Maintains MoonLake Immunotherapeutics(MLTX.US) With Sell Rating, Raises Target Price to $11 - 富途牛牛
MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs - TipRanks
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rating Upgraded by Zacks Research - MarketBeat
Decoding MoonLake Immunotherapeutics (MLTX): A Strategic SWOT Insight - GuruFocus
(MLTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛
MoonLake Immunotherapeutics (NASDAQ:MLTX) Posts Earnings Results - MarketBeat
Quarterly Earnings: Is MoonLake Immunotherapeutics stock a falling knife or bargain buyJuly 2025 Volume & Consistent Return Strategy Ideas - baoquankhu1.vn
Lifesci Capital Has Optimistic Outlook of MLTX Q4 Earnings - MarketBeat
MoonLake Immunotherapeutics SEC 10-K Report - TradingView
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Unveiling a 12.8% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Analysts’ Opinions Are Mixed on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Alpha Tau Medical Ltd (DRTS) and Oric Pharmaceuticals (ORIC) - The Globe and Mail
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Positive Phase 2 S-OLARIS Trial Results - simplywall.st
MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal (NASDAQ:MLTX) - Seeking Alpha
MoonLake turns the tables on sonelokimab with positive data - The Pharma Letter
Citi Maintains MoonLake Immunotherapeutics(MLTX.US) With Sell Rating, Raises Target Price to $6 - 富途牛牛
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $20 to $34 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Price Target Increased by 11.25% to 22.30 - Nasdaq
Oppenheimer Adjusts Price Target on MoonLake Immunotherapeutics to $35 From $30, Maintains Outperform Rating - marketscreener.com
Guggenheim Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $20 - 富途牛牛
Needham & Company LLC Issues Positive Forecast for MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Raised to $30.00 - MarketBeat
MoonLake Immunotherapeutics Investor Day: HS BLA on Track, axSpA Phase 2 Data Highlights Imaging Wins - MarketBeat
MoonLake Expects To File Sonelokimab For HS Later In 2026 - Citeline News & Insights
MoonLake touts Phase II sonelokimab results in spine disease study - FirstWord Pharma
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):